Amgen

Q3 2026
Speakers

Nov 3, 2026 · 62 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Good afternoon, everyone, ?and welcome to our third quarter of 2026 Earnings Call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Myrtle Gordon, Jay Bradner, ?and Thomas Dietrich. Through the course of our discussion today, ?we will use non-GAP financial measures to describe our performance and have provided appropriate reconciliations within the materials that accompany this call.

We will also make some forward-looking looking statements, which are qualified by our Safe Harbor statement. And please note that actual results can vary materially. Over to you, Bob.

Passages & reports (7)
  • Good afternoon, everyone,
  • and
  • welcome to our third quarter of 2026 Earnings Call. Bob Bradway will lead the call today a…
  • and
  • Thomas Dietrich. Through the course of our discussion today,
  • we
  • will use non-GAP financial measures to describe our performance and have provided appropri…

Speaker 1

Unverified voice label

Good afternoon, and thank you for joining our call. Our results through the first three quarters of the year reflect the strength of our business across a broad range of products and pipeline molecules. This is exactly the kind of performance our strategy was designed to achieve. Strong commercial and operations execution and continued innovation from our research and development organization reinforce our confidence in Amgen's ability to deliver durable long-term growth.

For the latest quarter, total revenues grew a strong 8% year over year to $10.4 billion.

Passages & reports (2)
  • Good afternoon, and thank you for joining our call. Our results through the first three qu…
  • operations execution and continued innovation from our research and development organizati…

Our six key growth drivers grew 27% year over year and represented over 70% of our third quarter product sales. Across the portfolio, 17 products delivered double-digit sales growth, and 17 products are now annualizing at more than $1 billion based on third-quarter sales. ?We see significant opportunity to build on this momentum. Many of our medicines address large, underpenetrated disease areas where the majority of patients remain untreated.

Rapatha, Avenity, and Tesspire are clear examples of
?that. Our strong financial performance gives us the flexibility to invest in innovation and the capabilities needed to support future growth while delivering attractive returns to shareholders. In the third quarter, we generated $3.7 billion in free cash flow, increased our investment in research and development by 11% year over year, and invested another $600 million in the business through capital expenditures.

This was another productive quarter for our RD organization. We reported positive phase three results from three important programs: MDELTRA in small cell
lung cancer, where we are working to establish it as the cornerstone therapy, TES Spire in Eosinophilic Esophagitis, an area with significant unmet need, ?and dazodalobep in Chogren's disease, where no approved disease modifying therapies currently exist. I would note that each of these represents an established or potential first-in-class medicine with the opportunity to make a meaningful difference for patients while providing additional sources of long-term growth for AMGEN.

Likewise, our progress reflects the strength of our science and our commitment to pursuing novel approaches for serious diseases. That same focus guides our investment in programs such as Meritide, which is advancing through phase three development. Jay will discuss
these programs and our other clinical advances in more detail shortly. We're also leveraging technology, data-driven insights, and artificial intelligence across Amgen to improve the speed and efficiency of how we discover, develop, manufacture, and deliver medicine to patients.

We're encouraged by our
performance this quarter. Our broad portfolio, continued investment in advancing pipeline, give us confidence in Amgen's ability to deliver durable growth well into the next decade. I want to thank our colleagues around the world for their dedication to our mission to serve patients and for the quality of their work every ?day. With that, we'll turn it over to Murdo. ?

Thanks,
Bob.

Passages & reports (17)
  • Our six key growth drivers grew 27% year over year and represented over 70% of our third q…
  • annualizing at more than $1 billion based on third-quarter sales.
  • We
  • see significant opportunity to build on this momentum. Many of our medicines address large…
  • that.
  • Our strong financial performance gives us the flexibility to invest in innovation and the …
  • by 11% year over year, and invested another $600 million in the business through capital e…
  • lung cancer, where we are working to establish it as the cornerstone therapy, TES Spire in…
  • and
  • dazodalobep in Chogren's disease, where no approved disease modifying therapies currently …
  • for AMGEN. Likewise, our progress reflects the strength of our science and our commitment …
  • these programs and our other clinical advances in more detail shortly. We're also leveragi…
  • performance this quarter. Our broad portfolio, continued investment in advancing pipeline,…
  • day. With
  • that, we'll turn it over to Murdo.
  • Thanks,
  • Bob.

Speaker 2

Unverified voice label

Looking back at the third quarter, what stands out for me is the remarkable progress we've made across our late stage pipeline and broad inline portfolio. We've seen important positive clinical readouts, regulatory milestones, and record sales performance for several of our key medicines. The consistency of these achievements reflects the breadth and strength of Amgen today and reinforces our confidence in the growth opportunities ahead.

Our commercial performance reflects this progress. Product sales grew 8% year over year, and we have 17 products annualizing at more than $1 billion in sales. All six of our key growth drivers deliver double digit growth in the
quarter, together growing 27% year over year and now representing more than 70% of product sales. Starting with general medicine, Rapatha delivered $1.1 billion in third quarter sales, growing 37% year over year.

Rapatha's momentum continues to accelerate with U.S. average
weekly new to brand prescriptions increasing over 60% compared with the prior year. This growth is supported by increased urgency to treat in both secondary prevention and high risk primary prevention patients. With the landmark Basalea CB results, Rapatha is now the only PCS-K9 inhibitor with phase 3 cardiovascular outcomes evidence in both primary and secondary prevention.

We're seeing deepening conviction and adoption among cardiologists and accelerating use in primary care.
?The updated ACC and AHA guidelines reinforce earlier, more intensive LDL cholesterol lowering and support the use of PCS-K9 inhibitors without requiring prior treatment with the zetamide. The new guidelines, supported by Rapatha's differentiated outcomes data, strengthen clinical conviction that Rappatha should be the first choice when additional LDL cholesterol lowering is needed beyond STANS.

This year alone, we expect more than 3 million additional patients globally to start treatment with Rapatha. With an estimated 100 million patients worldwide still above their LDL-C goals, we are only beginning to
address the significant unmet ?need, giving us confidence in Rapatha's growth potential into the 2030s. Avenity sales increased 39% in the third quarter to $751 million, building on 38% year-over-year growth in the previous quarter.

In the United States, robust patient demand continues to drive momentum,
supported by an expanding prescriber base and deeper adoption among treating physicians. We're increasing investment to expand our reach among physicians and to help more patients access treatment with avenity. The opportunity remains significant, particularly when we consider the devastating consequences of osteoporotic fractures. One in two patients who experience a hip fracture do not regain their prefracture mobility.

This reinforces the importance of earlier intervention and our conviction
?in avenity's potential to help more women at very high fracture risk, including those who have not yet experienced a fracture. In Japan, Avenity maintains leadership in the bone builder category with nearly 60% volume share. Updated treatment guidelines and increasing use among treatment naive patients are supporting continued growth and reinforcing Avenity's important role in osteoporosis ?care.

Moving to inflammation,
?test buyer sales grew 43% year over year, reaching $538 million, driven by strong demand and severe uncontrolled asthma. Test buyer's growth continues to outperform the severe uncontrolled asthma market, with U.S. new to brand prescriptions growing 15% year over year versus 3% market growth. Test buyers achieved 34% new to brand prescription share among allergists in the US and continues to gain share among pulmonologists with substantial room for further adoption.

The consistent flow of strong clinical data continues to reinforce test buyers'
differentiated efficacy across inflammatory diseases. Phase three results in chronic rhinosinusitis with nasal bulbs demonstrated improvements in disease control and a reduction in the need for surgery. More recently, positive phase three results in neosinophilic esophagitis or EOE demonstrated meaningful improvements in key measures of disease activity and symptoms, highlighting another potential new opportunity for Test buyer to help more patients.

Turning to rare disease, this portfolio grew 21% year over year to $1.6 billion, reflecting continued momentum from additional
indications and disciplined execution of international expansion. We see opportunity to extend the reach of these treatments, improve outcomes for patients, and sustain meaningful growth well into the next decade. ?The PLISNA sales increased 191% year over year to $451 million in the third quarter, driven by strong patient demand across all approved indications.

UPLISNA offers a highly differentiated clinical profile, combining outstanding efficacy that resonates
with physicians and convenient twice-yearly dosing that benefits patients. This profile is supported by broad pair coverage ?and AMGEN's comprehensive patient support services, helping physicians initiate treatment and support continuity of care. ?In the US, the PLISNA is demonstrating significant growth in generalized myocania gravis or GMG, with new and continuing patients increasing 45% quarter over quarter.

Adoption is expanding among both biologic naive patients and those transitioning from other therapies, reinforcing our
confidence in the PLISNA's potential to establish market leadership in this category. In IgG4-related disease, long-term follow-up data from the Phase III mitigate study continued to reinforce Uplizna's durable efficacy profile. All patients who continued treatment with Uplizna remained flair-free through the first year of the open label extension, with more than 70% achieving complete remission without glucocorticoids.

These durable results, together with growing disease awareness and improved diagnosis, support our confidence in Uplizna's potential to help many more patients.

Passages & reports (33)
  • Looking back at the third quarter, what stands out for me is the remarkable progress we've…
  • the breadth and strength of Amgen today and reinforces our confidence in the growth opport…
  • quarter, together growing 27% year over year and now representing more than 70% of product…
  • weekly new to brand prescriptions increasing over 60% compared with the prior year. This g…
  • cardiovascular outcomes evidence in both primary and secondary prevention. We're seeing de…
  • The
  • updated ACC and AHA guidelines reinforce earlier, more intensive LDL cholesterol lowering …
  • be the first choice when additional LDL cholesterol lowering is needed beyond STANS. This …
  • address the significant unmet
  • need,
  • giving us confidence in Rapatha's growth potential into the 2030s. Avenity sales increased…
  • supported by an expanding prescriber base and deeper adoption among treating physicians. W…
  • patients who experience a hip fracture do not regain their prefracture mobility. This rein…
  • in
  • avenity's potential to help more women at very high fracture risk, including those who hav…
  • naive patients are supporting continued growth and reinforcing Avenity's important role in…
  • care.
  • Moving to inflammation,
  • test
  • buyer sales grew 43% year over year, reaching $538 million, driven by strong demand and se…
  • market growth. Test buyers achieved 34% new to brand prescription share among allergists i…
  • differentiated efficacy across inflammatory diseases. Phase three results in chronic rhino…
  • meaningful improvements in key measures of disease activity and symptoms, highlighting ano…
  • indications and disciplined execution of international expansion. We see opportunity to ex…
  • The
  • PLISNA sales increased 191% year over year to $451 million in the third quarter, driven by…
  • with physicians and convenient twice-yearly dosing that benefits patients. This profile is…
  • and
  • AMGEN's comprehensive patient support services, helping physicians initiate treatment and …
  • In
  • the US, the PLISNA is demonstrating significant growth in generalized myocania gravis or G…
  • confidence in the PLISNA's potential to establish market leadership in this category. In I…
  • flair-free through the first year of the open label extension, with more than 70% achievin…

UPisna continues to expand its reach internationally and is now launched in 25 markets outside the U.S. We see substantial opportunity for continued growth as we bring EPLISNA to more patients around the world and advance its development across additional autoimmune diseases. Topesa generated $526 million in third quarter sales, a 6% decline year over year, impacted by an inventory build in the third quarter of last year.

International adoption continues to build with particularly encouraging uptake in Japan since entering the market last year. Topesa has now launched in more than 20 countries worldwide, with three additional
markets planned for the remainder of 2026. ?Our biosimilar portfolio delivered 26% year-over-year growth, generating $977 million in sales in the third quarter. PadBlue, our biosimilar to ILEA, increased sales of 41% year over year to $300 million in a quarter.

Retina specialists recognize the benefits of
Pablo's convenient pre-filled syringe presentation, supported by AMGEN's established capabilities and biosimilar manufacturing and supply. Our next wave of biosimilar candidates for ILEA, HD, Opdevo, Petruda, and Ocrevis are in late-stage clinical development and represent large market opportunities. Turning to innovative oncology, the portfolio grew 21% year over year, generating $2.1 billion in sales in the third quarter. Blinsaito sales increased 27% year over year to $496 million in the third quarter.

This growth continues to reflect
broad prescribing across academic and community settings and increasing international adoption. Blinsaito's established role in treating B cell acute lymphoblastic leukemia demonstrates the strength of our biospecific T cell engager platform and its ability to deliver meaningful outcomes across different cancers.

Passages & reports (8)
  • UPisna continues to expand its reach internationally and is now launched in 25 markets out…
  • quarter sales, a 6% decline year over year, impacted by an inventory build in the third qu…
  • markets planned for the remainder of 2026.
  • Our
  • biosimilar portfolio delivered 26% year-over-year growth, generating $977 million in sales…
  • Pablo's convenient pre-filled syringe presentation, supported by AMGEN's established capab…
  • large market opportunities. Turning to innovative oncology, the portfolio grew 21% year ov…
  • broad prescribing across academic and community settings and increasing international adop…

MDELTRA sales more than doubled year over year to $406 million. Behind this commercial momentum is a medicine with the potential to make a profound difference for patients facing small cell lung cancer. These patients and their families have faced limited treatment options and poor survival outcomes for decades. MDELTRA is changing that. Our landmark Delphi 304 trial demonstrated a 40% reduction in the risk of death compared with chemotherapy in second line treatment.

MDELTA also offers convenient every two week dosing following initial step up period. We're making progress and reducing the burden
of treatment. The FDA recently shortened the recommended monitoring period for the first two doses from 22 to 24 hours to just 6 to 8 hours. Looking ahead, we're advancing alternative dosing schedules, subcutaneous administration, and has the potential to further improve convenience for patients and expand access and community settings.

The potential to help patients earlier in their treatment journey is even more exciting. And as Jay will discuss in more detail, we recently presented phase three results from the Delphi 305 study evaluating MDELTRA in combination with MFNSI in first line maintenance treatment.
?I was at the European Society for Medical Oncology Congress in Madrid when these findings were presented, and I was moved by the standing ovation from the audience.

The excitement we heard from oncologists about the potential to significantly extend patients' lives was remarkable.
?The magnitude of these results is difficult to overstate. More than eight additional months of median overall survival represents an extraordinary advance for patients facing this devastating disease. We're moving with urgency to advance regulatory discussions with health authorities and support timely consideration by clinical guideline organizations, including the NCCN, so these findings can translate into clinical practice as rapidly as possible. ?

We
believe MDELTRA has the potential to transform the treatment of small cell lung cancer and with additional regulatory approvals become a cornerstone therapy across multiple stages of small cell lung cancer. Our portfolio has significant potential for deeper market penetration, additional indications, and global expansion. We're confident in our ability to deliver sustained growth well into the next decade while reaching more patients around the world.

And now I'll turn it over to Jay.

Passages & reports (12)
  • MDELTRA sales more than doubled year over year to $406 million. Behind this commercial mom…
  • MDELTRA is changing that. Our landmark Delphi 304 trial demonstrated a 40% reduction in th…
  • of treatment. The FDA recently shortened the recommended monitoring period for the first t…
  • access and community settings. The potential to help patients earlier in their treatment j…
  • I
  • was at the European Society for Medical Oncology Congress in Madrid when these findings we…
  • The
  • magnitude of these results is difficult to overstate. More than eight additional months of…
  • guideline organizations, including the NCCN, so these findings can translate into clinical…
  • We
  • believe MDELTRA has the potential to transform the treatment of small cell lung cancer and…
  • additional indications, and global expansion. We're confident in our ability to deliver su…

Speaker unclear

?Thank you, Murdo, and good afternoon. This quarter we

Passages & reports (1)
  • Thank you, Murdo, and good afternoon. This quarter we

Speaker 2

reported three positive ?phase three readouts ?across three serious diseases M Deltra

Passages & reports (5)
  • reported three positive
  • phase
  • three readouts
  • across three serious diseases
  • M Deltra

Speaker unclear

?in small cell lung cancer, TESPIRE in

Passages & reports (1)
  • in small cell lung cancer, TESPIRE in

Speaker 2

Eosinophilic esophagitis,

Passages & reports (1)
  • Eosinophilic esophagitis,

Speaker unclear

?and

Passages & reports (1)
  • and

Speaker 3

Unverified voice label

dazodalyback ?in Schourne's disease. These results reflect ?our RD strategy that focuses on first ?in class and best in class medicines for serious diseases with high unmet ?need. Each advance represents meaningful progress for patients and physicians and meaningful potential for long term growth. ?As Myrtle introduced, MDETRA is our DLL3 targeted biospecific T cell engager currently approved in second line or later small cell lung cancer, and the second approved medicine arising from our bite platform. ?

At
the European Society for Medical Oncology Conference, we presented practice-changing results for MDLTRA from the Delphi 305 study that evaluates MDLTRA plus MFINSI versus MFNSI alone as first-line maintenance treatment. ?The combination of MDLTR to MFINSI brought a median overall survival of 21.1 months versus 12.7 months with MFINSI alone. The results are notable in a challenging clinical setting where current medicines deliver only a modest improvement in overall survival.

Median follow-up at the data
cutoff was 15.9 months, and we will report final survival benefit as these data mature. Longer follow-up of 30 months from the phase 1B first line maintenance study of M Deltra with anti PDL1 therapy was also presented at ESMO, remarkably featuring a median overall survival of 37 months. These results are unprecedented in small cell lung cancer. ?The safety profile of M Deltra and Delphi 305 was consistent with the clinical experience to date.

Cytokine release syndrome and ICANNs were primarily low grade and occurred mostly after the first two doses. Delphi 305 permitted one to two hour monitoring time, which could support outpatient administration and
broader uptake. Given the transformative benefit observed, we are now working to rapidly file with regulatory authorities around the world. If approved in first line maintenance, MDELTRA could address the needs of 23,000 patients in the U.S.

alone, importantly used earlier in the treatment journey and for a longer duration of
therapy. We are pursuing a broad clinical program to establish MDLTRA as the cornerstone therapy for patients with small cell lung cancer. This program includes evaluating MDELTRA in earlier stage disease, novel combinations including antibody drug conjugates, and in other DLL3 expressing cancers. Turning to TESFIR, which targets TSLP, an upstream driver of inflammation in airways and other tissues, we recently presented positive results from the crossing study ?in Eosinophilic esophagitis, or EOE.

EOE is another epithelial-driven Eosinophilic inflammatory disease alongside severe asthma
?and chronic rhinocitositis with nasal polyps. EOE affects more than 470,000 people in the U.S. Nearly half of patients with this devastating disease remain inadequately controlled with existing treatments. ?The Phase III crossing study evaluated TESPIRE in adolescents and adults with symptomatic uncontrolled EOE. At week 24, the study met both co-primary endpoints, demonstrating improved histologic remission and improved swallowing symptoms compared with placebo.

These benefits
were sustained through week 52. This is the first time sustained efficacy through 52 weeks has been shown for a biologic ?in a placebo-controlled EOE trial. Multiple secondary endpoints were also met as TES buyer improved measures of underlying inflammation, swallowing symptoms, and endoscopic disease activity. Together with every four-week dosing, these results support TES buyer's potential as an important treatment option for patients with EOE and add to the evidence for targeting TSLP across serious diseases driven by eosinophilic inflammation. ?

For
patients with Schoprin's disease, we are targeting CD40 ligand signaling with dazodolybep in two phase three trials in systemic and in symptomatic disease. Schogrin's can affect multiple organ systems and cause persistent dryness, fatigue, and pain. There are no approved disease-modifying therapies for Schoprin's disease. ?In systemic Schobrin's disease, we are excited by the positive clinically meaningful results of dazodalibeth in the placebo controlled phase 3 OASIS 301 study. ?

The
study met its primary endpoint with statistically significant improvement from baseline S dye of 5.6 points with monthly dosing and 5.2 points with quarterly dosing, or 1.8 and 1.4 point placebo adjusted improvement, respectively. ?The treatment effect was observed as early as week four and sustained through the end of study at week 48. Importantly, Dazodalibep also met key secondary endpoints for patient reported dryness, with statistically significant improvements in DASPRI and ESPRI scores with monthly dosing.

Dazodalibep was generally well tolerated, whether administered monthly or quarterly. We'll present the detailed data at ACR on November eleventh and await the completion of our second phase 3 study in symptomatic Schoogrim's disease expected later this year. Beyond these three important
phase 3 advances, we recently reported at EADV the positive phase 2 data for Dexdilimab in primary discoid lupus or DLE. Dexdilimab targets ILT7 to reduce plasmacytoid dendritic cells and address type 1 interferon mediated inflammation.

Passages & reports (43)
  • dazodalyback
  • in Schourne's disease.
  • These results reflect
  • our RD strategy that
  • focuses on first
  • in class
  • and best in class medicines for serious diseases with high unmet
  • need.
  • Each advance represents meaningful progress for patients and physicians and meaningful pot…
  • As
  • Myrtle introduced, MDETRA is our DLL3 targeted biospecific T cell engager currently approv…
  • At
  • the European Society for Medical Oncology Conference, we presented practice-changing resul…
  • The
  • combination of MDLTR to MFINSI brought a median overall survival of 21.1 months versus 12.…
  • cutoff was 15.9 months, and we will report final survival benefit as these data mature. Lo…
  • months. These results are unprecedented in small cell lung cancer.
  • The
  • safety profile of M Deltra and Delphi 305 was consistent with the clinical experience to d…
  • broader uptake. Given the transformative benefit observed, we are now working to rapidly f…
  • therapy. We are pursuing a broad clinical program to establish MDLTRA as the cornerstone t…
  • cancers. Turning to TESFIR, which targets TSLP, an upstream driver of inflammation in airw…
  • in
  • Eosinophilic esophagitis, or EOE. EOE is another epithelial-driven Eosinophilic inflammato…
  • and
  • chronic rhinocitositis with nasal polyps. EOE affects more than 470,000 people in the U.S.…
  • The
  • Phase III crossing study evaluated TESPIRE in adolescents and adults with symptomatic unco…
  • were sustained through week 52. This is the first time sustained efficacy through 52 weeks…
  • in
  • a placebo-controlled EOE trial. Multiple secondary endpoints were also met as TES buyer im…
  • EOE and add to the evidence for targeting TSLP across serious diseases driven by eosinophi…
  • For
  • patients with Schoprin's disease, we are targeting CD40 ligand signaling with dazodolybep …
  • disease-modifying therapies for Schoprin's disease.
  • In
  • systemic Schobrin's disease, we are excited by the positive clinically meaningful results …
  • The
  • study met its primary endpoint with statistically significant improvement from baseline S …
  • The
  • treatment effect was observed as early as week four and sustained through the end of study…
  • Dazodalibep was generally well tolerated, whether administered monthly or quarterly. We'll…
  • phase 3 advances, we recently reported at EADV the positive phase 2 data for Dexdilimab in…

DLE can cause permanent scarring, skin pigment changes, and hair loss. ?In the study, both doses of Daxdilimab met the primary endpoint with improvement in active skin disease observed as early as week four and sustained through week 24. ?At week 24, Daxdilamab improved baseline Classy A by 10.2 points at the lower dose and 9.9 points at the higher dose. The corresponding placebo adjusted Class EA improvements of 6.0 and 5.7 points respectively were both statistically significant.

Dexteromab was well tolerated, with no serious adverse events or deaths reported. Based on these results, we are advancing Dexteromab into phase three development.
?As you can see, we've been working hard to execute the late stage portfolio and enjoyed terrific results this quarter. Elsewhere in the portfolio, we are focused on developing important new medicines in our late stage pipeline. ?For patients with prostate cancer, we are rapidly advancing xaluritamic in both early stage and advanced disease, extending the reach of our T cell engager platform.

For individuals with obesity and related conditions, we are advancing our comprehensive phase three maritime development programming. This quarter, we completed
enrollment of both phase three sleep apnea studies, our cardiovascular outcome study, and initiated the first of three phase three studies in type 2 diabetes. Meritide is emerging as the first monthly therapy for obesity with the potential for as few as four or six doses per year. ?

The
meritime program is designed to establish how individuals can start and stay on meritide and how others can switch from other GLP 1 based medicines and stay on meritide. Our goal is to make long-term treatment easier for patients, to sustain weight loss, and enjoy durable health benefits. I'd like to thank my colleagues across Amgen for their continued focus on patients and their commitment to advancing innovative medicines for serious diseases.

I'll now turn it over to Thomas for the financial update. Thank you, Jay. As many of you know, this is my second chapter at Amgen. I spent nearly a
decade here earlier in my career working with Bob and the team. Since then, I've served as CFO of three public companies with responsibilities spanning

Passages & reports (16)
  • DLE can cause permanent scarring, skin pigment changes, and hair loss.
  • In
  • the study, both doses of Daxdilimab met the primary endpoint with improvement in active sk…
  • At
  • week 24, Daxdilamab improved baseline Classy A by 10.2 points at the lower dose and 9.9 po…
  • Dexteromab was well tolerated, with no serious adverse events or deaths reported. Based on…
  • As
  • you can see, we've been working hard to execute the late stage portfolio and enjoyed terri…
  • For
  • patients with prostate cancer, we are rapidly advancing xaluritamic in both early stage an…
  • enrollment of both phase three sleep apnea studies, our cardiovascular outcome study, and …
  • per year.
  • The
  • meritime program is designed to establish how individuals can start and stay on meritide a…
  • benefits. I'd like to thank my colleagues across Amgen for their continued focus on patien…
  • decade here earlier in my career working with Bob and the team. Since then, I've served as…

Speaker unclear

?finance,

Passages & reports (1)
  • finance,

Speaker 4

Unverified voice label

strategy, transformation, and operations. I also gained experience ?in a more consumer-focused healthcare environment and in a rare disease setting. So I come back to Amgen knowing the company well, but also looking at it with fresh eyes, informed by my experiences over the past 12 years. Today I'm pleased to join you for my first quarterly earnings call as Amgen CFO. I look forward to maintaining Amjun's active engagement with the investment community and the financial discipline that investors expect.

My top priorities are straightforward. One, working with my colleagues as a team to drive long-term growth through
consistent execution of our strategy and operational efficiency. Two, maintaining Amgen's disciplined approach to capital allocation. You should expect continuity here as we balance investment in the best innovation and future growth with returning capital to shareholders. Let's now turn to our third quarter financial results. Our strong third quarter performance reinforces confidence in our six key growth drivers.

Together, they reflect the breadth and depth of our business and continue to provide a strong foundation for
durable growth well into the next decade. We continue to invest in advancing our pipeline while delivering strong operating results. ?In the third quarter, our non-gap operating margin was 47%. Non-gap RD spending increased 11% year over year, driven by higher spend in research and early pipeline, including business development activity.

We continue to invest in the innovation that will drive future
growth, including Maritite, Dazadalibap, and Xaloidomic, as well as our marketed medicines, including Mdeltra, Repassa, and Aplisna. SGA expenses decreased 1% year on year, mainly driven by the timing of investments and to a lesser extent, our ongoing productivity efforts. We generated $3.7 billion in free cash flow, reflecting continued momentum across the business and enabling us to continue investing for future growth.

Capital expenditures were $600 million in the quarter,
including investments across our US manufacturing sites in North Carolina, Ohio, and Puerto Rico. We continue to expect capital expenditures of approximately $2.6 billion in 2026 to scale manufacturing capacity for commercial growth and to prepare for a potential maritite launch. In addition, we returned capital to shareholders through attractive dividend payments of $2.52 per share, representing a 6% increase compared to the third quarter of 2025.

Turning now to the outlook for
the business for the remainder of 2026. We are pleased with the strength of our execution and are raising our 2026 guidance ranges for both revenue and non-gap EPS. We now expect 2026 total revenues in the range of $38.9 billion to $39.7 billion and non-GAAP earnings per share between $22.90 and $23.70. And let me highlight several additional guidance items.

We now anticipate non GAAP other income and expense
to be in the range of $2 to $2.1 billion of expense in 2026. We continue to expect the full year non-gap operating margin as a percentage of product sales to be roughly 45 to 46 percent. As we look to the fourth quarter, we expect a meaningful sequential increase in operating expenses consistent with our established pattern of higher spending in the final quarter of the year.

Specifically, we expect a sequentially higher cost of sales margin due to changes in our sales mix and higher profit share
expenses and higher SGA expense due to the aforementioned timing of investments in the third quarter and continued investment in our marketed products. We expect other revenue to be approximately $1.9 billion for the full year. We expect a non gap tax rate in the range of 15 to 16.5%.

We expect share repurchases not to exceed $3 billion. Looking ahead to 2027, we do not anticipate a step down in operating margin compared with
our 2026 guidance. We will continue to allocate resources efficiently, balancing investment in growth with disciplined expense management. As we close out the year, we remain focused on executing our strategy, advancing our growth drivers, investing in the best innovation, and maintaining our rigorous financial discipline that supports our ability to deliver durable growth well into the next decade.

I am grateful to work with all our colleagues worldwide in our mission to serve patients. This concludes our financial update.

Passages & reports (21)
  • strategy, transformation, and operations. I also gained experience
  • in
  • a more consumer-focused healthcare environment and in a rare disease setting. So I come ba…
  • Amgen CFO. I look forward to maintaining Amjun's active engagement with the investment com…
  • consistent execution of our strategy and operational efficiency. Two, maintaining Amgen's …
  • shareholders. Let's now turn to our third quarter financial results. Our strong third quar…
  • durable growth well into the next decade. We continue to invest in advancing our pipeline …
  • In
  • the third quarter, our non-gap operating margin was 47%. Non-gap RD spending increased 11%…
  • growth, including Maritite, Dazadalibap, and Xaloidomic, as well as our marketed medicines…
  • ongoing productivity efforts. We generated $3.7 billion in free cash flow, reflecting cont…
  • including investments across our US manufacturing sites in North Carolina, Ohio, and Puert…
  • and to prepare for a potential maritite launch. In addition, we returned capital to shareh…
  • the business for the remainder of 2026. We are pleased with the strength of our execution …
  • billion to $39.7 billion and non-GAAP earnings per share between $22.90 and $23.70. And le…
  • to be in the range of $2 to $2.1 billion of expense in 2026. We continue to expect the ful…
  • quarter, we expect a meaningful sequential increase in operating expenses consistent with …
  • expenses and higher SGA expense due to the aforementioned timing of investments in the thi…
  • non gap tax rate in the range of 15 to 16.5%. We expect share repurchases not to exceed $3…
  • our 2026 guidance. We will continue to allocate resources efficiently, balancing investmen…
  • the best innovation, and maintaining our rigorous financial discipline that supports our a…

I will now hand it over to Bob for QA.

Passages & reports (1)
  • I will now hand it over to Bob for QA.

Speaker 1

Okay, let's open up the line for questions and why don't you remind our callers of the procedure?

Passages & reports (1)
  • Okay, let's open up the line for questions and why don't you remind our callers of the pro…

Speaker 5

Unverified voice label

Thank you. If you would like to ask a question, please press star followed by one on your telephone keypad. If for any reason you would like to remove that question, please press star followed by one. Again, to ask a question, press star one. Our first question comes from Salvine Richter from Goldman Sachs.

Passages & reports (1)
  • Thank you. If you would like to ask a question, please press star followed by one on your …

Questions & answers

Speaker 5

Please go ahead, your line is

Passages & reports (1)
  • Please go ahead, your line is

Speaker unclear

?open.

Passages & reports (1)
  • open.

Speaker 6

Unverified voice label

Thanks, good afternoon. On the back of the positive phase three results in systemic Shobrin's disease, could you help us to think about the confidence or kind of handicap how we should think about the readout here in the symptomatic patients and then speak to the regulatory paths for this program overall? Thank

Passages & reports (2)
  • Thanks, good afternoon. On the back of the positive phase three results in systemic Shobri…
  • for this program overall? Thank

Speaker unclear

?you. Thanks,

Passages & reports (1)
  • you. Thanks,

Speaker 2

Alvine. This is Jay. We're delighted by the results of the systemic study 301 and the efficacy that we observe for both the primary endpoint on S dye placebo-adjusted as well as the impact on secondary dryness are quite encouraging. It is hard to read through, though, from 301 into 303, the systemic to the symptomatic. These ?are different patient populations, they're being studied separately, and this is important to tease ?out the possibility of impact on these 434 patients in the 303 study.

So we'll have more to um

Passages & reports (6)
  • Alvine. This is Jay. We're delighted by the results of the systemic study 301 and the effi…
  • 301 into 303, the systemic to the symptomatic. These
  • are
  • different patient populations, they're being studied separately, and this is important to …
  • out
  • the possibility of impact on these 434 patients in the 303 study. So we'll have more to um

Speaker 3

uh to to say shortly after we see data in Q4 of this year. ?Uh regarding the regulatory path going forward, um, ?you know, this is a very competitive space of late, which is good for patients because for years there was very little progress. DAZO really represents the first therapeutic to show efficacy in the systemic setting, also on symptoms and durable out to end of study.

Um so um we have nothing to say here today,
um, but we uh look forward to a a consideration of these data.

Passages & reports (6)
  • uh to to say shortly after we see data in Q4 of this year.
  • Uh
  • regarding the regulatory path going forward, um,
  • you
  • know, this is a very competitive space of late, which is good for patients because for yea…
  • um, but we uh look forward to a a consideration of these data.

Speaker unclear

?Okay,

Passages & reports (1)
  • Okay,

Speaker 1

let's go to the next question.

Passages & reports (1)
  • let's go to the next question.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 5

you, Salvine. Our next question comes from Terrence Flynn from Morgan Stanley. Please go ahead. Your line is

Passages & reports (1)
  • you, Salvine. Our next question comes from Terrence Flynn from Morgan Stanley. Please go a…

Speaker unclear

?open.

Passages & reports (1)
  • open.

Speaker 1

Great. Uh thanks

Passages & reports (1)
  • Great. Uh thanks

Speaker unclear

?for taking the questions and uh congrats on all the progress. Um I

Passages & reports (1)
  • for taking the questions and uh congrats on all the progress. Um I

Speaker 7

Unverified voice label

know Thomas, you talked about some of the CapEx investments uh that you guys are making for uh ahead of the Maritide launch. Um is there any consideration to maybe ramping down the biosimilars business to make even more capacity for that for that launch. Would that also be on the table? And then the kind of related question is can you tell us, Jay, if you guys have access to the blinded tolerability data from the ongoing maritime phase three trials?

Thank

Passages & reports (2)
  • know Thomas, you talked about some of the CapEx investments uh that you guys are making fo…
  • kind of related question is can you tell us, Jay, if you guys have access to the blinded t…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

I I can uh answer that for for you, Terrence is Bob. Um ?we obviously we we consider all options when it comes to uh managing capacity, but we feel very confident about our ability to continue to be a reliable supplier of high quality biosimilars. So that's that's not a strain for us. And our capacity expansion is really designed for for larger quantities of protein than what you're referring to with the biosimilars ?program.

On the other question, Jay, do you want
?to take a shot?

Passages & reports (8)
  • I I can uh answer that for for you, Terrence is Bob. Um
  • we
  • obviously we we consider all options when it comes to uh managing capacity, but we feel ve…
  • you're referring to with the biosimilars
  • program.
  • On the other question, Jay, do you want
  • to
  • take a shot?

Speaker unclear

?Sure.

Passages & reports (1)
  • Sure.

Speaker 2

Thanks,

Passages & reports (1)
  • Thanks,

Speaker 3

Terrence,

Passages & reports (1)
  • Terrence,

Speaker 2

for the question. We are in 2026 just noses down with discipline data generation on Meritide. And the Meritide studies are being um carried

Passages & reports (1)
  • for the question. We are in 2026 just noses down with discipline data generation on Meriti…

Speaker 3

out with um you know uh uh a

Passages & reports (1)
  • out with um you know uh uh a

Speaker 2

total adherence to good clinical practices. Um we'll have more to share around the efficacy and tolerability of meritide at the time

Passages & reports (1)
  • total adherence to good clinical practices. Um we'll have more to share around the efficac…

Speaker 3

that these studies read

Passages & reports (1)
  • that these studies read

Speaker unclear

?out.

Passages & reports (1)
  • out.

Speaker 0

Next question, please, Julianne.

Passages & reports (1)
  • Next question, please, Julianne.

Speaker 5

Our next question comes from Akash Shawari from Jeffries. Please go ahead. Your line is open.

Passages & reports (1)
  • Our next question comes from Akash Shawari from Jeffries. Please go ahead. Your line is op…

Speaker unclear

?Hey, uh thanks so

Passages & reports (1)
  • Hey, uh thanks so

Speaker 3

much. You know, uh hearing your team talk about the phase three Showbrin's data versus phase two and systemic, ?I think one of the things I've noticed is your team was surprised with the onset of effect, and it might have been better than what you saw in phase two. Can you talk about um what we are seeing on onset of effect um with the systemic trial and how that reads across to the symptomatic study that's um coming up?

And then just any comment on the maritime pen study. I know you just started a study looking at maritide with uh an at-home auto injector. Uh what gave you the confidence to start that study now? And do we have any visibility on what what um auto injector dose
you would be having in that trial? Thank

Passages & reports (5)
  • much. You know, uh hearing your team talk about the phase three Showbrin's data versus pha…
  • I think
  • one of the things I've noticed is your team was surprised with the onset of effect, and it…
  • study that's um coming up? And then just any comment on the maritime pen study. I know you…
  • you would be having in that trial? Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Thanks. I'll take ?the questions. This is Jay. ?As I shared a moment ago, um we were delighted, but maybe not surprised, by the impact of dazodalibep and Schobrin's disease. We were building on a

Passages & reports (5)
  • Thanks. I'll take
  • the questions.
  • This is Jay.
  • As
  • I shared a moment ago, um we were delighted, but maybe not surprised, by the impact of daz…

Speaker 3

very strong phase two data set after ?all. Um the significant 1.8 placebo adjusted improvement with uh monthly dosing on the SDI and 1.4 on the Q12 week are uh in in line with our expectations and strong results, and the effect on dryness as well. We were um hoping and expecting to see as well. Um the um read through, I think I've already uh covered a moment ago, but you asked about onset.

And um,
?you know, here is a

Passages & reports (6)
  • very strong phase two data set after
  • all.
  • Um the significant 1.8 placebo adjusted improvement with uh monthly dosing on the SDI and …
  • the um read through, I think I've already uh covered a moment ago, but you asked about ons…
  • you
  • know, here is a

Speaker 2

potential advantage of something that

Passages & reports (1)
  • potential advantage of something that

Speaker 3

targets

Passages & reports (1)
  • targets

Speaker 2

active inflammatory

Passages & reports (1)
  • active inflammatory

Speaker 3

signaling like C D40 and CD40 ligand. We got a lot of experience at this company with B cell depletion. Um and with B cell depletion, there can be a delay in onset in some circumstances, though in many diseases we haven't experienced that with the plisma. So to see effect at week four is highly consistent with our mechanistic thesis that as an inhibitor of CD40 ligand CD40 signaling, you have this chance for an immediate inhibition on B cell driven inflammation.

But moreover, as C D40 is also highly expressed on salivary gland ductal epithelial

Passages & reports (2)
  • signaling like C D40 and CD40 ligand. We got a lot of experience at this company with B ce…
  • highly consistent with our mechanistic thesis that as an inhibitor of CD40 ligand CD40 sig…

Speaker 2

cells, cells

Passages & reports (1)
  • cells, cells

Speaker 3

and can therefore drive local inflammation through interaction with activated T cells or otherwise. Um it could be sensible that dazodalibev would work as early as four weeks, where we saw statistically significant improvement already that proved durable through the end of study. ?Um so thanks for calling out that feature. It is a nice feature of a molecule directed at an active signaling

Passages & reports (3)
  • and can therefore drive local inflammation through interaction with activated T cells or o…
  • Um
  • so thanks for calling out that feature. It is a nice feature of a molecule directed at an …

Speaker 2

pathway that it might, in some circumstances, work faster.

Passages & reports (1)
  • pathway that it might, in some circumstances, work faster.

Speaker 1

Obviously we've got ?a ton of experience with auto injectors, so ?I don't think there's anything particularly interesting about the the study that you're referencing. But Jay, feel free to add anything more if you'd like.

Passages & reports (5)
  • Obviously we've got
  • a
  • ton of experience with auto injectors, so
  • I
  • don't think there's anything particularly interesting about the the study that you're refe…

Speaker 2

No, uh we've been pretty consistent in sharing that uh merit is expected ultimately to be delivered in a patient-friendly, single chamber, handheld auto injector. We have significant experience here as Bob shared. We've taken a fairly standard approach to its development and going well so far.

Passages & reports (1)
  • No, uh we've been pretty consistent in sharing that uh merit is expected ultimately to be …

Speaker 1

Okay, let's go to the next question and maybe just remind our colours so that we can try to get to everybody tonight. If you could hold yourself to one question, that would be great. Casey and his team will be around and all of us are available if you have other questions you need to get uh in front of us uh later in the day.

But let's let's go ahead to the next caller.

Passages & reports (2)
  • Okay, let's go to the next question and maybe just remind our colours so that we can try t…
  • to get uh in front of us uh later in the day. But let's let's go ahead to the next caller.

Speaker 5

Our next question comes from Michael Yee from UBS. Please go ahead. Your line is open.

Passages & reports (1)
  • Our next question comes from Michael Yee from UBS. Please go ahead. Your line is open.

Speaker unclear

?Uh great,

Passages & reports (1)
  • Uh great,

Speaker 2

thanks.

Passages & reports (1)
  • thanks.

Speaker unclear

?One question for

Passages & reports (1)
  • One question for

Speaker 3

Bob. Uh Bob, uh Amdren has been quieter, I guess, on the MA uh front uh in a period of record MA deal making. Could you just comment about your perspective about what you think is going on? Is your desperation factor not high? You're very busy. Maybe you're just more excited about what you've got. Maybe just talk a little bit about that ?and whether we should or should not necessarily continue to expect bolt-ons or whatever you're thinking.

Thank

Passages & reports (4)
  • Bob. Uh Bob, uh Amdren has been quieter, I guess, on the MA uh front uh in a period of rec…
  • got. Maybe just talk a little bit about that
  • and
  • whether we should or should not necessarily continue to expect bolt-ons or whatever you're…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

Well I'm not sure, Michael, that I ?would um acknowledge the premise of the question, but it uh it what I would say is our business development focus is very consistent. As we've said for some time, we're looking for uh opportunities that align well with ?our uh four therapeutic uh areas of focus. Um you know, we're focused on uh delivering consistent long-term growth, and we uh feel confident we're on track to do ?that.

Um, you know, through time, um obviously a meaningful portion of our revenues come from molecules that we license or acquired, and I think that'll continue to be true through time. So um we'd like to think that we're disciplined, uh Michael, in the way that we allocate capital both internally and externally. And I'd
like to think when particularly when we go externally that we see a path for our shareholders to earn a return and not just for the selling shareholders to earn a return.

Great.

Passages & reports (8)
  • Well I'm not sure, Michael, that I
  • would
  • um acknowledge the premise of the question, but it uh it what I would say is our business …
  • our
  • uh four therapeutic uh areas of focus. Um you know, we're focused on uh delivering consist…
  • that.
  • Um, you know, through time, um obviously a meaningful portion of our revenues come from mo…
  • like to think when particularly when we go externally that we see a path for our sharehold…

Speaker 0

Next question, please, Julianne.

Passages & reports (1)
  • Next question, please, Julianne.

Speaker 5

Our next question comes from Yaron Werber from TD Cowan. Please go ahead. Your line is open.

Passages & reports (1)
  • Our next question comes from Yaron Werber from TD Cowan. Please go ahead. Your line is ope…

Speaker 7

Great. Thanks so much. So maybe ?a quick question on

Passages & reports (3)
  • Great. Thanks so much. So maybe
  • a quick
  • question on

Speaker unclear

?the

Passages & reports (1)
  • the

Speaker 7

upcoming shore grind data. The efficacy looked very

Passages & reports (1)
  • upcoming shore grind data. The efficacy looked very

Speaker 3

good on the monthly and Q3 months. Daspery is sort of a new endpoint that you're validating from the phase ?two. Is that going ?to support ?the US filing ?while SPRI is going to

Passages & reports (9)
  • good on the monthly and Q3 months. Daspery is sort of a new endpoint that you're validatin…
  • two. Is that
  • going
  • to
  • support
  • the
  • US filing
  • while SPRI is going
  • to

Speaker unclear

?support the European

Passages & reports (1)
  • support the European

Speaker 7

filing ?for the symptomatic

Passages & reports (3)
  • filing
  • for the
  • symptomatic

Speaker 3

study? And then

Passages & reports (1)
  • study? And then

Speaker unclear

?if you don't mind, can

Passages & reports (1)
  • if you don't mind, can

Speaker 3

you

Passages & reports (1)
  • you

Speaker unclear

?file for both Q4 and Q3 months given uh they both hit on the

Passages & reports (1)
  • file for both Q4 and Q3 months given uh they both hit on the

Speaker 7

primary,

Passages & reports (1)
  • primary,

Speaker 3

but only Q month hit on the secondary in the first study on dryness? Thank

Passages & reports (1)
  • but only Q month hit on the secondary in the first study on dryness? Thank

Speaker unclear

?you. Uh

Passages & reports (1)
  • you. Uh

Speaker 2

thank you. Especially in between the readouts of these two phase threes, we're probably not going to go deep today on our full regulatory strategy. ?Um, but you are correct that there are different preferences around endpoints in the US and

Passages & reports (3)
  • thank you. Especially in between the readouts of these two phase threes, we're probably no…
  • Um,
  • but you are correct that there are different preferences around endpoints in the US and

Speaker 3

rest of the world. And we've taken this very much to the heart in the design of these two studies, in the primary and secondary endpoints.

Passages & reports (1)
  • rest of the world. And we've taken this very much to the heart in the design of these two …

Speaker 5

Our next question comes from Chris Schott from JP Morgan. Please go ahead. Your line is open.

Passages & reports (1)
  • Our next question comes from Chris Schott from JP Morgan. Please go ahead. Your line is op…

Speaker 0

Great. ?Thanks so much. Just had

Passages & reports (3)
  • Great.
  • Thanks so
  • much. Just had

Speaker unclear

?a question on

Passages & reports (1)
  • a question on

Speaker 7

Mdeltra.

Passages & reports (1)
  • Mdeltra.

Speaker 3

Can you just elaborate a little bit

Passages & reports (1)
  • Can you just elaborate a little bit

Speaker 7

more

Passages & reports (1)
  • more

Speaker 3

about how you're thinking about the opportunity unlocked with the 305 data? And as maybe as part of that, how quickly you believe the product can ramp following the the ESMO data. ?As part of that answer, just could you also talk about the the reduced monitoring requirements for the drug as a as well. I'm just trying to get a sense of how much of a hurdle monitoring had been for for uptake in the later line settings, and that obviously seems to be addressed in this this earlier line setting as well.

Thanks so

Passages & reports (4)
  • about how you're thinking about the opportunity unlocked with the 305 data? And as maybe a…
  • As
  • part of that answer, just could you also talk about the the reduced monitoring requirement…
  • this earlier line setting as well. Thanks so

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 2

Thanks, Chris. It's Myrtle here. So um on the monitoring we've we've got a uh an improvement already uh just approved by the FDA that's now in our label in the second line setting with monitoring of of less than six hours now. So that that improves from the 22 to 24 hours that were in the original label, and now we're in a much shorter monitoring period.

So that's already helping the um you know the ability for uh primarily community uh oncology clinics to be able to initiate second line patients within DELTRA. Um
when as Jay mentioned in the three oh five study, the monitoring actually goes down to one to two hours. And so there'll be uh hopefully a a further improvement in the label as we uh extend that to the frontline maintenance indication.

And then then M
Delta becomes a very straightforward, very simple product to initiate in that frontline maintenance setting with obviously uh a profound survival benefit to be had. So I think, ?you know, this is a medicine, given how novel it is, that we've been very careful to ensure patient safety. We're now evolving in our understanding of it. And as with moved into earlier disease settings, we see that this is a much, much better tolerated medicine.

We really only had one patient in
Delphi 305 ?with cytokine release syndrome of grade three. All the other patients that experienced cytokine release syndrome experienced grades one and two. So, what does that mean for the opportunity? Well, it means that we believe we've established a new cornerstone therapy. We believe that nothing else thus far in the category has been able to demonstrate the kind of profound overall survival effect that we ?have.

And I would expect that with things like updated NCCN guidelines with additional awareness of these data, uh the the behavior change in the clinic will be rapid. Um obviously we're moving as quick as we can uh to ensure regulatory filings and approvals and all the rest
of it, ?but uh we are ready to support um the rate of change that clinicians will affect.

Um
?you know I'll just say you know I've been talking to our field medical teams who have been out there this week and last week uh post presentation of the data at ESMO. And you know, I'm not alone in my enthusiasm for these data. Our practicing oncologists are blown away by just the magnitude of effect and the safety profile that we're seeing now in an earlier disease setting.

Passages & reports (18)
  • Thanks, Chris. It's Myrtle here. So um on the monitoring we've we've got a uh an improveme…
  • 24 hours that were in the original label, and now we're in a much shorter monitoring perio…
  • when as Jay mentioned in the three oh five study, the monitoring actually goes down to one…
  • Delta becomes a very straightforward, very simple product to initiate in that frontline ma…
  • you
  • know, this is a medicine, given how novel it is, that we've been very careful to ensure pa…
  • Delphi 305
  • with
  • cytokine release syndrome of grade three. All the other patients that experienced cytokine…
  • nothing else thus far in the category has been able to demonstrate the kind of profound ov…
  • have.
  • And I would expect that with things like updated NCCN guidelines with additional awareness…
  • of it,
  • but
  • uh we are ready to support um the rate of change that clinicians will affect. Um
  • you
  • know I'll just say you know I've been talking to our field medical teams who have been out…
  • magnitude of effect and the safety profile that we're seeing now in an earlier disease set…

Speaker 0

Julian, next question, please.

Passages & reports (1)
  • Julian, next question, please.

Speaker 5

Our next question comes from Umar Raffet from Evercore ISI. Please go ahead. Julian is open.

Passages & reports (1)
  • Our next question comes from Umar Raffet from Evercore ISI. Please go ahead. Julian is ope…

Speaker 3

Hi guys. Thanks again

Passages & reports (1)
  • Hi guys. Thanks again

Speaker unclear

?for taking my question. And I just wanted to echo the sentiment from ESMO

Passages & reports (1)
  • for taking my question. And I just wanted to echo the sentiment from ESMO

Speaker 3

on the groundbreaking data. Um Murdo, maybe just ?to expand on Chris's ?question and just to ?make it easier for ?investors to understand the magnitude of what we're dealing with here, is it possible or is it realistic for us to assume something approaching 20,000 plus patients ?in US ?being on

Passages & reports (13)
  • on the groundbreaking data. Um Murdo, maybe just
  • to
  • expand on Chris's
  • question and just
  • to
  • make it
  • easier for
  • investors to understand
  • the magnitude of what we're dealing with here, is it possible or is it realistic for us to…
  • in
  • US
  • being
  • on

Speaker unclear

?Tart Latimab? And do you envision the maintenance opportunity in first line alone being five billion plus uh with induction trial next year adding additional upside? Thank you very much. Well,

Passages & reports (1)
  • Tart Latimab? And do you envision the maintenance opportunity in first line alone being fi…

Speaker 2

Boomer, I think you know me by now you know the Amgen team by now that we don't issue ?you know product-specific uh guidance, but you can tell um the answer to to ?uh Chris's question that we're we're extremely uh excited about the data set that have been generated here. You know, the the the opportunity is definitely um an interesting one given how rapidly patients progress on in this disease area.

And so in second line, you're quite limited as to the addressable
patient population because unfortunately not many patients make it to second line. Their disease progresses too rapidly and they end up in in hospice and they end up dying. And so as you move into the earlier lines, you know, the small cell lung cancer addressable population in the US is 35,000. So it's it's a decent sized patient population.

The question is, you know, how big is it in each setting in frontline maintenance? Um, you know, but but as I said to Chris, this is going to be a very rapid adoption and we're going to see hopefully, hopefully, many patients on
MDELTRA for a long period of time. And so the duration of treatment here might be quite long as well. But I would like to turn it over to Jay on other clinical development work that we're doing on the molecule.

Passages & reports (8)
  • Boomer, I think you know me by now you know the Amgen team by now that we don't issue
  • you
  • know product-specific uh guidance, but you can tell um the answer to to
  • uh
  • Chris's question that we're we're extremely uh excited about the data set that have been g…
  • patient population because unfortunately not many patients make it to second line. Their d…
  • 35,000. So it's it's a decent sized patient population. The question is, you know, how big…
  • MDELTRA for a long period of time. And so the duration of treatment here might be quite lo…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

thanks, Umer. The development of M Deltra remains a source of real activity here at Amgen. We're working hard to complete ?the limited stage small cell lung cancer study that is an event-driven study as well. Now, having seen ?the benefit of MDELTRA used in the maintenance setting of frontline induction and maintenance use of MDELTRA. We've completed, as you may know, a study of MDLTRA that establishes an alternate dosing capability.

And this is very helpful as we start to imagine combinations of MDLTRA with emerging agents,
such as antibody drug conjugates. MDELTRA is showing dramatic data when combined with

Passages & reports (6)
  • thanks, Umer. The development of M Deltra remains a source of real activity here at Amgen.…
  • the
  • limited stage small cell lung cancer study that is an event-driven study as well. Now, hav…
  • the
  • benefit of MDELTRA used in the maintenance setting of frontline induction and maintenance …
  • such as antibody drug conjugates. MDELTRA is showing dramatic data when combined with

Speaker 2

chemotherapy, and

Passages & reports (1)
  • chemotherapy, and

Speaker 3

there's every expectation then that ADCs delivering chemotherapy should be comparably active. And we ?have undertaken studies with B7H3 and DLL3, and we'll ?have more to share there in the future. But just as Murdo said, not only do these combinations and advances in the use of M Deltra as a cornerstone of small cell lung cancer therapy lead to increased response rates, but durability.

And we're very hopeful
?that as the data from the Delphi study presented in the presidential at ESMO and published in the New England Journal recently, that as these data mature, that patients will reveal to us the full benefit of the medicine. The phase 1B frontline maintenance study, Delphi 303, that was also presented at ESMO has matured. And with a median follow-up of 30.8 months, we saw ?a median overall survival of 37.9 months, which is just unheard of in this disease setting.

So we're very pleased with the development so far, but we have a lot of wood to chop for these patients going forward.

Passages & reports (10)
  • there's every expectation then that ADCs delivering chemotherapy should be comparably acti…
  • have
  • undertaken studies with B7H3 and DLL3, and we'll
  • have
  • more to share there in the future. But just as Murdo said, not only do these combinations …
  • that
  • as the data from the Delphi study presented in the presidential at ESMO and published in t…
  • with a median follow-up of 30.8 months, we saw
  • a
  • median overall survival of 37.9 months, which is just unheard of in this disease setting. …

Speaker 0

Shall we end next question, please?

Passages & reports (1)
  • Shall we end next question, please?

Speaker 5

Our next question comes from David Ann Sellum from Piper Sandler. Please go ahead. Your line is open.

Passages & reports (1)
  • Our next question comes from David Ann Sellum from Piper Sandler. Please go ahead. Your li…

Speaker unclear

?Hey, thanks. So have a Dax Dilamab

Passages & reports (1)
  • Hey, thanks. So have a Dax Dilamab

Speaker 2

uh question. On the phase three, are you going to explore a broader cutaneous lupus population or will it be specific to discoid um lupus? That's number one. And then just thinking about this ?this market, can you talk ?about um sizing in terms ?of uh how you think about uh cutaneous lupus in that population relative to the SLE population and how these are two distinct populations and how ?that informs your physician targeting?

Is this a dermatology call point or a rheumatology
?call point or a

Passages & reports (11)
  • uh question. On the phase three, are you going to explore a broader cutaneous lupus popula…
  • this market, can you
  • talk
  • about
  • um sizing in terms
  • of
  • uh how you think about uh cutaneous lupus in that population relative to the SLE populatio…
  • that informs
  • your physician targeting? Is this a dermatology call point or a rheumatology
  • call
  • point or a

Speaker unclear

?bit of both?

Passages & reports (1)
  • bit of both?

Speaker 7

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 3

Thanks for the question. I'll start Myrtle, and maybe you can weigh in on the outlook for the medicine. Thanks for asking about Daxylamab. We're very pleased with the activity observed so far in discoid lupus, a prevalent disease, 20 to 50 humans per 100,000, and 5 to 10 percent may progress to SLE. You surely appreciate that there have been innumerable mechanisms of action that have failed patients with lupus in its various manifestations. ?

And
in our phase two study, the effect on Class EA, where an improvement from seven points from baseline is considered clinically meaningful broadly in this population of those greater than or equal to eight at baseline. ?You know, improvements that we saw were negative 10 and negative 9.9 for the lower and the higher doses at week 24. And so we're very taken with this medicine in the cutaneous manifestations of lupus.

We have not as yet described completely our phase three design, and we will do that in the future. But
it's not lost on us that we've stumbled upon a very exciting and hopeful mechanism targeting these plasma cytoid dendritic cells in um in this disease. Myrtle?

Passages & reports (7)
  • Thanks for the question. I'll start Myrtle, and maybe you can weigh in on the outlook for …
  • SLE. You surely appreciate that there have been innumerable mechanisms of action that have…
  • And
  • in our phase two study, the effect on Class EA, where an improvement from seven points fro…
  • You
  • know, improvements that we saw were negative 10 and negative 9.9 for the lower and the hig…
  • it's not lost on us that we've stumbled upon a very exciting and hopeful mechanism targeti…

Speaker unclear

?No,

Passages & reports (1)
  • No,

Speaker 2

I would just add that you know the the prescribing population of physicians here, primarily dermatologists, which obviously we have ?good uh MGEN capabilities and experience there. Um and uh for the few uh rheumatologists that will pick it up, again, we have you know strong medical and field commercial teams covering those customers.

Passages & reports (3)
  • I would just add that you know the the prescribing population of physicians here, primaril…
  • good
  • uh MGEN capabilities and experience there. Um and uh for the few uh rheumatologists that w…

Speaker 0

Julianne, next question, please.

Passages & reports (1)
  • Julianne, next question, please.

Speaker 5

Our next question comes from Evan Siegerman from Bemo Capital Markets. Please go ahead. Your line is open.

Passages & reports (1)
  • Our next question comes from Evan Siegerman from Bemo Capital Markets. Please go ahead. Yo…

Speaker unclear

?Hi guys, thank you so much for taking my question. I think, Jay, when we met in the small group meeting back in September, we

Passages & reports (1)
  • Hi guys, thank you so much for taking my question. I think, Jay, when we met in the small …

Speaker 3

suggested ?that although meritide is administered monthly or even less frequently,

Passages & reports (3)
  • suggested
  • that
  • although meritide is administered monthly or even less frequently,

Speaker unclear

?like

Passages & reports (1)
  • like

Speaker 7

the um side effect

Passages & reports (1)
  • the um side effect

Speaker unclear

?duration is comparable in length to what you get with weekly um incertons. I would love it if you could expand more on how you can measure that in kind of a phase, you know, one of and any of your

Passages & reports (1)
  • duration is comparable in length to what you get with weekly um incertons. I would love it…

Speaker 3

trials. And

Passages & reports (1)
  • trials. And

Speaker unclear

?more broadly, just given how much the

Passages & reports (1)
  • more broadly, just given how much the

Speaker 3

space in obesity has rapidly evolved even since then, you know, remind

Passages & reports (1)
  • space in obesity has rapidly evolved even since then, you know, remind

Speaker unclear

?us how meritide fits within kind of this evolving landscape. Thank you so much.

Passages & reports (1)
  • us how meritide fits within kind of this evolving landscape. Thank you so much.

Speaker 3

Thanks. Why don't I start to talk, Murdo, about ?the um interesting and reassuring, if not exciting, dissociation between ?the pharmacokinetics of meritide and the duration of symptomatology. If you could pick up the back half of the question about segmentation. First, I would just say, irrespective of why I think it is true, it is true that this medicine that has a very long half-life designed for tonic

Passages & reports (6)
  • Thanks. Why don't I start to talk, Murdo, about
  • the
  • um interesting and reassuring, if not exciting, dissociation between
  • the
  • pharmacokinetics of meritide and the duration of symptomatology. If you could pick up the …
  • tonic

Speaker 2

activation of

Passages & reports (1)
  • activation of

Speaker 3

GLP1 receptors as well as inhibition of GIP receptors

Passages & reports (1)
  • GLP1 receptors as well as inhibition of GIP receptors

Speaker 2

that has conferred activity for weight loss and type 2 diabetes with monthly dosing, every eight-week dosing, and as we described, every 12 week dosing. It is a fact born out of prospective clinical investigation that though the durable disease activity of the medicine is quite long lived, like the molecule, the symptoms aren't. This is true also for weekly injectable GLP1 peptides, and so we're not surprised to see ?it.

Now, how do we measure it, you ask? Um, here um we've done very exhaustive diaries in early phase clinical investigation to understand the onset, frequency, severity, and duration of symptoms. We've shared some of these early plots that we call Manhattan plots that reveal
the duration of symptoms should they arise. To date, meritide is proven very well tolerated. Its target doses and like all GLP1s, benefits from dose escalation.

But the durable activity of the medicine does not come with a durable side effect side
effect profile, where side effects to date are where observed mostly mild, sometimes moderate, and uh rather short-lived for a few days. Myrtle? ?Yeah, it's an interesting observation, Evan, on the on the amount of activity in this category. There are certainly a lot of daily orals being developed.

There's a lot of weekly injectables being developed, some even trying to stretch to monthly. Um but what what we've not seen is uh you know a bona fide
monthly uh drug in development that could be dosed as infrequently as six times or four times a year. And we continue to believe that maritite is unique and differentiated in that aspect. It's a simple three step dose escalation, two months, you're up to your uh your first maintenance dose and then you can find the most convenient dose for your weight loss journey thereafter.

So I feel like we've got a compelling offering. We're you know obviously looking forward to seeing the phase three data when they read
?out. And we're excited about coming into the market and helping many, many patients reach their weight loss goals. We've also got a broad clinical program, as you know, and that means that we'll also be able to help patients with type 2 diabetes and ASCVD and sleep apnea, among others.

others.

Passages & reports (12)
  • that has conferred activity for weight loss and type 2 diabetes with monthly dosing, every…
  • activity of the medicine is quite long lived, like the molecule, the symptoms aren't. This…
  • it.
  • Now, how do we measure it, you ask? Um, here um we've done very exhaustive diaries in earl…
  • the duration of symptoms should they arise. To date, meritide is proven very well tolerate…
  • effect profile, where side effects to date are where observed mostly mild, sometimes moder…
  • Yeah,
  • it's an interesting observation, Evan, on the on the amount of activity in this category. …
  • monthly uh drug in development that could be dosed as infrequently as six times or four ti…
  • maintenance dose and then you can find the most convenient dose for your weight loss journ…
  • out.
  • And we're excited about coming into the market and helping many, many patients reach their…

Speaker 0

Julianne, next question, please.

Passages & reports (1)
  • Julianne, next question, please.

Speaker 5

Our next question comes from Jeff Mecham from City. Please go ahead. Your line is open.

Passages & reports (1)
  • Our next question comes from Jeff Mecham from City. Please go ahead. Your line is open.

Speaker 7

Hey guys, uh, thanks for taking the question. Uh had a similar one for Jay or for Mer Murdo. So ahead of the maritime data next year, ?I wanted to ask how you guys are thinking about the commercial approach. So m mostly thinking about the dynamics of the new Medicare bridge program, you know, payer receptivity. ?How you're thinking about the OUS markets uh in advance of data.

Thank

Passages & reports (5)
  • Hey guys, uh, thanks for taking the question. Uh had a similar one for Jay or for Mer Murd…
  • I
  • wanted to ask how you guys are thinking about the commercial approach. So m mostly thinkin…
  • How
  • you're thinking about the OUS markets uh in advance of data. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Thanks for the question, Jeff. I look, I think I I would start first with we're very focused on making sure that consumers and patients are very much in an in the focus of our go-to-market strategy. I think what we've seen in this category is that um patients have a much uh more important role to play in uh uh activating uh and advocating for their own care and their own weight loss journey.

So first and foremost, that that is absolutely the priority. We will scale and size accordingly. We obviously have a great cardiometabolic uh team here at Amgen and we'll uh
be ready to go to market with Maritite. I think on the on the access and reimbursement front, we expect our unique differentiated profile uh to help uh secure uh access and coverage. And obviously, we're interested in seeing what other uh government access programs evolve to over time.

I think it's it's good that we've
?got Medicare access in this category. I think it should be expanded. XUS, I think, is going to be tougher. I ?think it's going to continue to be very much a consumer driven market, XUS. But we are hopeful with outcomes data in ASCBD and with type 2 diabetes data and other quote unquote hard endpoint clinical programs, then that we'll be able to secure reimbursement in many markets outside the US as

Passages & reports (9)
  • Thanks for the question, Jeff. I look, I think I I would start first with we're very focus…
  • role to play in uh uh activating uh and advocating for their own care and their own weight…
  • be ready to go to market with Maritite. I think on the on the access and reimbursement fro…
  • programs evolve to over time. I think it's it's good that we've
  • got
  • Medicare access in this category. I think it should be expanded. XUS, I think, is going to…
  • think
  • it's going to continue to be very much a consumer driven market, XUS. But we are hopeful w…
  • markets outside the US as

Speaker unclear

?well.

Passages & reports (1)
  • well.

Speaker 1

Okay, let's uh let's take two more questions and then we'll, as I said earlier, be available if there are some of you who didn't get a chance to ask questions on the call. Let's go two more.

Passages & reports (1)
  • Okay, let's uh let's take two more questions and then we'll, as I said earlier, be availab…

Speaker 5

Our next question comes from Matt Phipps from William Blair. Please go ahead. Your line is open.

Passages & reports (1)
  • Our next question comes from Matt Phipps from William Blair. Please go ahead. Your line is…

Speaker unclear

?Thanks

Passages & reports (1)
  • Thanks

Speaker 7

for taking my question throughout a good quarter. Uh with both the Updevo and Keychuda uh BLAs filed, just curious what your assumptions are around being able to commerce when you can commercially launch those. And how do you think about penetrating the market that is kind of being moved to subcutaneous formulation? Thank

Passages & reports (1)
  • for taking my question throughout a good quarter. Uh with both the Updevo and Keychuda uh …

Speaker unclear

?you. Yeah

Passages & reports (1)
  • you. Yeah

Speaker 1

obviously this is a competitive space here, so we're not going to have a whole lot to to share with ?you at this point, Matt. But as you heard from Murdo's remarks, um our focus is on uh developing these medicines, having them available for patients. Uh and uh again we've established a pretty good track record here as ?a leader in biosimilars. ?But Mirdo, feel free to jump in if you want to add any further, Keller.

Passages & reports (7)
  • obviously this is a competitive space here, so we're not going to have a whole lot to to s…
  • you
  • at this point, Matt. But as you heard from Murdo's remarks, um our focus is on uh developi…
  • a
  • leader in biosimilars.
  • But
  • Mirdo, feel free to jump in if you want to add any further, Keller.

Speaker 2

Well, as we as we always say about our focus on biosimilars, we'll be we'll be a first or first wave with those launches, which is really important to establish decent competitive position. And we believe that we're we're

Passages & reports (1)
  • Well, as we as we always say about our focus on biosimilars, we'll be we'll be a first or …

Speaker unclear

?there. All

Passages & reports (1)
  • there. All

Speaker 1

right, let's go to the last question, please.

Passages & reports (1)
  • right, let's go to the last question, please.

Speaker unclear

?My

Passages & reports (1)
  • My

Speaker 5

last question comes from Alex Hammond from Wolf Research. Please go ahead. Your line is open. ?Hey guys,

Passages & reports (3)
  • last question comes from Alex Hammond from Wolf Research. Please go ahead. Your line is op…
  • Hey
  • guys,

Speaker 6

thanks for squeezing me in. So, unlike small cell lung cancer, a large share of prostate cancer care occurs within neurology groups and community practices that have little experience managing CRS. ?So, I guess how are you planning to bring cellulitamig to those sites and how

Passages & reports (3)
  • thanks for squeezing me in. So, unlike small cell lung cancer, a large share of prostate c…
  • So,
  • I guess how are you planning to bring cellulitamig to those sites and how

Speaker 5

much could the fully outpatient cohort or

Passages & reports (1)
  • much could the fully outpatient cohort or

Speaker unclear

?sub Q version change that? And I guess also how important is it to not need a

Passages & reports (1)
  • sub Q version change that? And I guess also how important is it to not need a

Speaker 6

biomarker to

Passages & reports (1)
  • biomarker to

Speaker unclear

?help adoption compared to other treatments that require them? Thank you.

Passages & reports (1)
  • help adoption compared to other treatments that require them? Thank you.

Speaker 1

Terrific. Thanks for the question. Jay, why don't you share your thoughts?

Passages & reports (1)
  • Terrific. Thanks for the question. Jay, why don't you share your thoughts?

Speaker 2

Yeah, I'll

Passages & reports (1)
  • Yeah, I'll

Speaker 3

share on the back

Passages & reports (1)
  • share on the back

Speaker 2

to side. Then, Murdo, perhaps you could talk about implementing T cell engagers, where we just have so much experience, truly the leading company in the sector. So for sure, um helping the adoption of this medicine is experience with it. And um uh uh building a comfort uh with T-cell engagers as a therapeutic isn't as much about the doctor as it is about the care environment, I can say, as a doctor.

Um the reduced monitoring will go a long way to helping, as well as a fully outpatient cohort, which we have presented at ESMO in phase 1B, which demonstrated for Xaluridamig,
our C1 CD35 specific that you referenced, the feasibility for a more convenient administration setting. I will say this is not trivial, but those same centers approach many other non-trivial medicines. ?And so we have every expectation that through clinical investigation as well as evidence generation, we will establish confidence and and comfort for prescribing urologists as needed.

You sort of threw me the basketball right under the hoop with your question around biomarkers. It helps a
?lot to not need a biomarker in order to enroll patients and bring access to a medicine. We have some medicines that, of course, require ?it, but here the quite high, if not characteristic, expression of steep one in prostate cancer affords a chance to bring this medicine to patients without the need for stratification or qualification by a confirmatory biomarker.

Myrda? Yeah, we've
got obviously extensive experiences, Jay mentioned, in bringing biospecific T cell engagers into different uh therapeutic uh contexts. We've we've we've learned a lot from our work in uh hematology with blensito, now in solid tumor with M DELTRA, and we have established an actual field organization we call our biospecific operations team, who help with the operationalization in clinics on how to make sure that patients get the appropriate monitoring, the appropriate information at point of care.

So that team is up and running. We've had it since uh before the launch
of MDETRA. We're now running it at scale for Mdeltra, and we would apply that to the GEU oncology space as ?well. We've established a field medical presence with these customers and these clinicians. And we also partner very closely with patient advocacy organizations. This was ?a key success factor in Small

Passages & reports (16)
  • to side. Then, Murdo, perhaps you could talk about implementing T cell engagers, where we …
  • T-cell engagers as a therapeutic isn't as much about the doctor as it is about the care en…
  • our C1 CD35 specific that you referenced, the feasibility for a more convenient administra…
  • And
  • so we have every expectation that through clinical investigation as well as evidence gener…
  • lot
  • to not need a biomarker in order to enroll patients and bring access to a medicine. We hav…
  • it,
  • but here the quite high, if not characteristic, expression of steep one in prostate cancer…
  • got obviously extensive experiences, Jay mentioned, in bringing biospecific T cell engager…
  • actual field organization we call our biospecific operations team, who help with the opera…
  • of MDETRA. We're now running it at scale for Mdeltra, and we would apply that to the GEU o…
  • well.
  • We've established a field medical presence with these customers and these clinicians. And …
  • a
  • key success factor in Small

Speaker unclear

?Cell, where

Passages & reports (1)
  • Cell, where

Speaker 3

the patient advocates are ?very good at making patients aware

Passages & reports (3)
  • the patient advocates are
  • very good at
  • making patients aware

Speaker 2

of how to self-monitor and how ?to identify any type of side effect profile that could ?be a side effect profile related to cytokine release syndrome. ?So really a lot of experience being applied to the ?GU space that I think will be very helpful helpful in ensuring

Passages & reports (9)
  • of how to self-monitor and how
  • to
  • identify any type of side effect profile that could
  • be
  • a side effect profile related to cytokine release syndrome.
  • So
  • really a lot of experience being applied to the
  • GU
  • space that I think will be very helpful helpful in ensuring

Speaker 3

patient safety and ease

Passages & reports (1)
  • patient safety and ease

Speaker 2

of adoption.

Passages & reports (1)
  • of adoption.

Speaker 1

All right. Well, thank you all for joining our call. I think I can speak for the group here that we're heartened by your focus on the sources ?of long term growth that have emerged with clinical data over the last few weeks. As again, I hope you can appreciate the businesses performing well, the leadership executing well, and we're looking forward to finishing the year strong.

And we'll look forward also to gathering with all of you next year to review the fourth
quarter and to get launched into 2027. So thanks for your support. We'll talk to you soon.

Passages & reports (4)
  • All right. Well, thank you all for joining our call. I think I can speak for the group her…
  • of
  • long term growth that have emerged with clinical data over the last few weeks. As again, I…
  • quarter and to get launched into 2027. So thanks for your support. We'll talk to you soon.
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 0. Unassigned words: 421. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T03:09:00.826Z.
Transcript version v1-eac6188a12b701c463ab · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.